FDA

FDA_logo

Why This Isn’t the End of Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) saw its shares get halved just Tuesday morning alone, following a business update regarding its Lambert-Eaton myasthenic syndrome (LEMS) treatment. The company provided an update ...
Read Full Story »
market crash

4 Companies That Have Destroyed Shareholders

As earnings season is underway, some analysts are expecting earnings disappointments going forward, as S&P Global Market Intelligence expects earnings for the S&P 500 to shrink by about 8% in ...
Read Full Story »
Medical interface

Why TransEnterix Shares Are in Free Fall

TransEnterix Inc. (NYSEMKT: TRXC) watched its shares in free fall on Thursday morning following a devastating judgment by the U.S. Food and Drug Administration (FDA). The company announced after the markets ...
Read Full Story »
hospital entrance

Can BioMarin Make Treating Hemophilia More Affordable?

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ready to break above the $1 billion revenue barrier in 2016. This is a feat that marks a major hurdle for many biotech and emerging ...
Read Full Story »
FDA_logo

Are Analysts Realistic on Clovis Oncology Now?

Clovis Oncology Inc. (NASDAQ: CLVS) was down about 5% Tuesday and was down even more Wednesday after the Oncologic Drugs Advisory Committee voted against its lung cancer drug. The committee ...
Read Full Story »
clinical trials

Is PTC Therapeutics on the Road to Recovery?

PTC Therapeutics Inc. (NASDAQ: PTCT) saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy (nmDMD) treatment. The company announced that the National Institute for ...
Read Full Story »
IPO

inVentiv Files for IPO

inVentiv Group Holdings has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in the filing, but ...
Read Full Story »
clinical trials

Regeneron Rises on Positive Top-Line Results

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), in conjunction with Sanofi, released top-line results for its most recent late-stage study. The companies announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab ...
Read Full Story »
Test tubes

Opko Health Stumbles Over FDA Letter

Opko Health Inc. (NYSE: OPK) saw its shares slide in Wednesday’s regular trading session following the release of a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA). ...
Read Full Story »
FDA_logo

Acadia Posts Big Win With FDA Approval

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) saw its shares on the rise again this week following an incredibly positive U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) vote. ...
Read Full Story »
SEC

SEC Charges Aveo With Misleading Investors

The U.S. Securities and Exchange Commission (SEC) has just announced fraud charges against Aveo Pharmaceuticals Inc. (NASDAQ: AVEO) and three former executives for misleading investors concerning the company’s efforts to ...
Read Full Story »
automatic inspection machine

Inovio Fails to Impress With HPV Business Update

Inovio Pharmaceuticals Inc. (NASDAQ: INO) made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment. The company announced a clinical strategy update to take its INO-3112 HPV ...
Read Full Story »
biotech word cloud

8 Major Biopharma Events Coming Later in 2016 and in 2017

Companies in the pharmaceutical industry generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There can be a fair amount of risk ...
Read Full Story »
Female patient on gurney

Why Merrill Lynch Sees Acadia Rising Another 60%

Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) surged early on Monday morning. This company is under the spotlight by the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee, which is ...
Read Full Story »
clinical trials

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) led the bulls on Monday morning following the release of its mid-stage clinical trial results. The company announced positive top-line data from two clinical trials evaluating ...
Read Full Story »